Smart Drug Delivery Systems Market Size & Trend Report, 2022-2030
According to Nova one advisor, the global Smart Drug Delivery Systems market size was valued at USD 8.12 billion in 2022 and is predicted to hit USD 36.9 billion by 2030 with a registered CAGR of 15.9% during the forecast period 2022 to 2030.
Smart drug delivery system or connected drug delivery system uses different approaches, formulations, technologies, and devices to deliver drugs to specific sites or targets. Drugs are released at proper rates at the sites of action in the process. Majority of the innovations in the pharmaceutical industry are motivated by the need to improve patient compliance. Drug formulators focusing on therapeutic areas need to pay close attention to patient experience in order to optimize adherence. Reduced dosage frequency and improved ease of administration are critical to providing the best possible experience for patients and encouraging adherence to their treatment regimen.
Thus, emerging therapeutics in SDDS are now turning into conventional modes of drug delivery to specific sites. Patients are shifting toward controlled drug delivery systems, as the healthcare sector's digitalization accelerates through the gradual integration of diagnostic point-of-care sensors and connected computation platforms into patients' daily routines. Internet of Things (IoT)-based devices such as wearable sensors can now measure functioning, respiration, biomarkers from sweat, and even an individual's emotional state. Metered dose inhalers, nebulizers, and dry powder inhalers are used for pulmonary drug delivery.
Report Scope of the Smart Drug Delivery Systems Market
|
Report Coverage |
Details |
|
Market Size |
USD 8.12 Billion by 2030 |
|
Growth Rate |
CAGR of 15.9% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Product, Drug Delivery Mode, Therapeutic Area, End-user, and Region, |
|
Companies Mentioned |
Abbott Laboratories, Adherium Ltd., Amiko Digital Health Limited, Becton, Dickinson and Company, BIOCORP, CeQur Corporation, Cognita Labs, E3D Elcam Drug Delivery Devices, H&T Presspart Manufacturing Ltd., HCmed Innovations Co., Ltd., Medtronic plc, Novo Nordisk, Phillips-Medisize, and Sonceboz |
Nanotechnology plays a key role in the development of SDDS and early detection and personalized treatment of cancer. Limitations associated with traditional cancer therapy administration such as reduced drug solubility, chemo-resistance, systemic toxicity, narrow therapeutic indices, and poor oral bioavailability can be addressed using nanoparticle-based drug-delivery systems. Smart drugs in nanotechnology include targeted drug delivery and extended-release drug-delivery systems that offer additional ways to overcome these limitations. Recently, R&D of highly efficient nanoparticles with improved delivery, bioavailability, and safety profiles gained prominence to provide SDDS with an extended drug release.
Rise in Demand for Wearable Injectors Fueling Connected Wearable Injectors Segment
In terms of product, the global smart drug delivery systems market has been classified into connected inhalers, connected autoinjectors, connected pen injectors, connected wearable injectors, add-on sensors, and others. The connected wearable injectors segment held the largest share of the market in 2021 and is expected to maintain its dominance during the forecast period. Growth of the segment can be ascribed to the rise in concerns over needle stick injuries, surge in geriatric population and prevalence of chronic diseases, and increase in demand for continuous health monitoring. According to the Centers for Disease Control and Prevention (CDC), approximately 385,000 injuries with contaminated needles and other sharps devices occur annually among hospital-based healthcare personnel. Injuries with contaminated needles and other sharp devices carry the risk of transmission of blood-borne viruses.
The connected autoinjectors segment is likely to grow significantly during the forecast period. Market players are launching new connected autoinjectors that improve patient experience. In May 2021, Phillips-Medisize, a Molex company, launched the Aria Smart Autoinjector platform to support medication management.
Better Patient Compliance Augmenting Adoption of Injectables
Based on delivery mode, the global smart drug delivery systems market has been segmented into injectable, inhalation, and oral. The injectable segment held substantial share of the market in 2021 due to benefits of injections such as better patient compliance, ease of application, and reduced dosage frequency and pain.
Increase in Prevalence of Diabetes and Cardiovascular Diseases Propelling Metabolic Disorders Segment
In terms of therapeutic area, the global smart drug delivery systems market has been classified into metabolic disorders, neurological disorders, respiratory disorders, hormonal disorders, and others. The metabolic disorders segment is anticipated to dominate the market during the forecast period, owing to the rise in prevalence of diabetes and cardiovascular diseases worldwide. According to the World Health Organization (WHO), about 422 million individuals across the globe are suffering from diabetes; most of these live in low-and middle-income countries. Furthermore, 1.5 million deaths are directly attributed to diabetes annually.
Growth in Number of Hospitals Across Globe
Based on end-user, the global smart drug delivery systems market has been segmented into hospitals, clinics, home care, ambulatory care settings, and others. The hospitals segment held the largest share of the market in 2021. This can be ascribed to the increase in number of hospitals and rise in adoption of smart drug delivery systems in these settings. According to the American Hospital Association (AHA), the number of hospitals in the U.S. rose from 5,564 in 2017 to 6,093 in 2022.
Regional Analysis of Global Smart Drug Delivery Systems Market
According to the smart drug delivery systems market analysis, North America dominated the global market in 2021 and is expected to maintain its position during the forecast period. Increase in R&D expenditure; rise in adoption of novel and improved devices; early availability of advanced technologies; growth in healthcare expenditure; and presence of sophisticated healthcare infrastructure and key market participants in the U.S. and Canada are driving the market in the region. Abbott Laboratories and Becton, Dickinson and Company have strong presence in the U.S.
According to the global smart drug delivery systems market forecast, Asia Pacific is expected to witness the fastest, double-digit growth due to the rise in geriatric population, increase in prevalence of cardiovascular diseases, expansion in healthcare infrastructure, and surge in medical tourism in the region. According to the Organization for Economic Cooperation and Development (OECD), India, Malaysia, Singapore, and Thailand are prominent medical tourism destinations in Asia Pacific.
Key Developments in Global Smart Drug Delivery Systems Market
Some of the prominent players in the Smart Drug Delivery Systems Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Smart Drug Delivery Systems market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Smart Drug Delivery Systems Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
5. Key Insights
5.1. Smart Insulin Pen - Brand Analysis
5.2. Insulin Pen Delivery Devices Available in the U.S.
5.3. Insights on Digitization of Diabetes: Opportunities & Challenges
5.4. Key Industry Events (Partnership, Merger & Acquisition, etc.)
5.5. COVID-19 Impact Analysis
6. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2030
6.3.1. Connected Inhalers
6.3.2. Connected Autoinjectors
6.3.3. Connected Pen Injectors
6.3.4. Connected Wearable Injectors
6.3.5. Add-on Sensors
6.3.6. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Delivery Mode, 2017–2030
7.3.1. Injectable
7.3.2. Inhalation
7.3.3. Oral
7.4. Market Attractiveness Analysis, by Drug Delivery Mode
8. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Therapeutic Area, 2017–2030
8.3.1. Metabolic Disorders
8.3.2. Neurological Disorders
8.3.3. Respiratory Disorders
8.3.4. Hormonal Disorders
8.3.5. Others
8.4. Market Attractiveness Analysis, by Therapeutic Area
9. Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017–2030
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Home Care
9.3.4. Ambulatory Care Settings
9.3.5. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2030
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Smart Drug Delivery Systems Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2030
11.2.1. Connected Inhalers
11.2.2. Connected Autoinjectors
11.2.3. Connected Pen Injectors
11.2.4. Connected Wearable Injectors
11.2.5. Add-on Sensors
11.2.6. Others
11.3. Market Value Forecast, by Drug Delivery Mode, 2017–2030
11.3.1. Injectable
11.3.2. Inhalation
11.3.3. Oral
11.4. Market Value Forecast, by Therapeutic Area, 2017–2030
11.4.1. Metabolic Disorders
11.4.2. Neurological Disorders
11.4.3. Respiratory Disorders
11.4.4. Hormonal Disorders
11.4.5. Others
11.5. Market Value Forecast, by End-user, 2017–2030
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Home Care
11.5.4. Ambulatory Care Settings
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2030
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Drug Delivery Mode
11.7.3. By Therapeutic Area
11.7.4. By End-user
11.7.5. By Country/Sub-region
12. Europe Smart Drug Delivery Systems Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2030
12.2.1. Connected Inhalers
12.2.2. Connected Autoinjectors
12.2.3. Connected Pen Injectors
12.2.4. Connected Wearable Injectors
12.2.5. Add-on Sensors
12.2.6. Others
12.3. Market Value Forecast, by Drug Delivery Mode, 2017–2030
12.3.1. Injectable
12.3.2. Inhalation
12.3.3. Oral
12.4. Market Value Forecast, by Therapeutic Area, 2017–2030
12.4.1. Metabolic Disorders
12.4.2. Neurological Disorders
12.4.3. Respiratory Disorders
12.4.4. Hormonal Disorders
12.4.5. Others
12.5. Market Value Forecast, by End-user, 2017–2030
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Home Care
12.5.4. Ambulatory Care Settings
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2030
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Drug Delivery Mode
12.7.3. By Therapeutic Area
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2030
13.2.1. Connected Inhalers
13.2.2. Connected Autoinjectors
13.2.3. Connected Pen Injectors
13.2.4. Connected Wearable Injectors
13.2.5. Add-on Sensors
13.2.6. Others
13.3. Market Value Forecast, by Drug Delivery Mode, 2017–2030
13.3.1. Injectable
13.3.2. Inhalation
13.3.3. Oral
13.4. Market Value Forecast, by Therapeutic Area, 2017–2030
13.4.1. Metabolic Disorders
13.4.2. Neurological Disorders
13.4.3. Respiratory Disorders
13.4.4. Hormonal Disorders
13.4.5. Others
13.5. Market Value Forecast, by End-user, 2017–2030
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Home Care
13.5.4. Ambulatory Care Settings
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2030
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Drug Delivery Mode
13.7.3. By Therapeutic Area
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Smart Drug Delivery Systems Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2030
14.2.1. Connected Inhalers
14.2.2. Connected Autoinjectors
14.2.3. Connected Pen Injectors
14.2.4. Connected Wearable Injectors
14.2.5. Add-on Sensors
14.2.6. Others
14.3. Market Value Forecast, by Drug Delivery Mode, 2017–2030
14.3.1. Injectable
14.3.2. Inhalation
14.3.3. Oral
14.4. Market Value Forecast, by Therapeutic Area, 2017–2030
14.4.1. Metabolic Disorders
14.4.2. Neurological Disorders
14.4.3. Respiratory Disorders
14.4.4. Hormonal Disorders
14.4.5. Others
14.5. Market Value Forecast, by End-user, 2017–2030
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Home Care
14.5.4. Ambulatory Care Settings
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2030
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Drug Delivery Mode
14.7.3. By Therapeutic Area
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2030
15.2.1. Connected Inhalers
15.2.2. Connected Autoinjectors
15.2.3. Connected Pen Injectors
15.2.4. Connected Wearable Injectors
15.2.5. Add-on Sensors
15.2.6. Others
15.3. Market Value Forecast, by Drug Delivery Mode, 2017–2030
15.3.1. Injectable
15.3.2. Inhalation
15.3.3. Oral
15.4. Market Value Forecast, by Therapeutic Area, 2017–2030
15.4.1. Metabolic Disorders
15.4.2. Neurological Disorders
15.4.3. Respiratory Disorders
15.4.4. Hormonal Disorders
15.4.5. Others
15.5. Market Value Forecast, by End-user, 2017–2030
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Home Care
15.5.4. Ambulatory Care Settings
15.5.5. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2030
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Drug Delivery Mode
15.7.3. By Therapeutic Area
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2021)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. Strategic Overview
16.3.1.5. SWOT Analysis
16.3.2. Adherium Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. Strategic Overview
16.3.2.5. SWOT Analysis
16.3.3. Amiko Digital Health Limited
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. Strategic Overview
16.3.3.5. SWOT Analysis
16.3.4. Becton, Dickinson and Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. Strategic Overview
16.3.4.5. SWOT Analysis
16.3.5. BIOCORP
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. Strategic Overview
16.3.5.5. SWOT Analysis
16.3.6. CeQur Corporation
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. Strategic Overview
16.3.6.5. SWOT Analysis
16.3.7. Cognita Labs
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. Strategic Overview
16.3.7.5. SWOT Analysis
16.3.8. E3D Elcam Drug Delivery Devices
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. Strategic Overview
16.3.8.5. SWOT Analysis
16.3.9. H&T Presspart Manufacturing Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. Strategic Overview
16.3.9.5. SWOT Analysis
16.3.10. HCmed Innovations Co., Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. Strategic Overview
16.3.10.5. SWOT Analysis
16.3.11. Medtronic plc
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. Strategic Overview
16.3.11.5. SWOT Analysis
16.3.12. Novo Nordisk
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. Strategic Overview
16.3.12.5. SWOT Analysis
16.3.13. Phillips-Medisize
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. Strategic Overview
16.3.13.5. SWOT Analysis
16.3.14. Sonceboz
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. Strategic Overview
16.3.14.5. SWOT Analysis
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers